Gaithersburg-Based NovaVax Initiates Trial For Combination COVID-19 And Flu Vaccine

GAITHERSBURG, Md. (WJZ) — NovaVax, a Gaithersburg-based biotechnology company, announced Wednesday it has enrolled participants successful a signifier 1/2 survey of a operation vaccine utilizing the company’s influenza and COVID-19 vaccines.

The survey volition measure the information and immune effect of the operation vaccine. The vaccine combines the NVX-CoV2373 Covid vaccine and the NanoFlu flu vaccine. The institution said some vaccines person produced beardown results arsenic standalone vaccines successful signifier 3 trials.

READ MORE: MD Casinos Bring In $168.5 Million In August, Agency Says

“This survey is the first-of-its-kind to measure the vaccine’s imaginable to induce a robust immune response, augmented by our Matrix-M adjuvant, against 2 life-threatening diseases simultaneously,” said Gregory M. Glenn, M.D., President of Research and Development astatine Novavax. “The operation of these 2 vaccines, which person individually delivered outstanding results with favorable information and tolerability profiles, whitethorn pb to greater efficiencies for the healthcare strategy and execute precocious levels of extortion against COVID-19 and influenza with a azygous regimen.”

The participants volition beryllium 640 steadfast adults 50- to 70-years-old who person antecedently tested affirmative for COVID-19 oregon vaccinated done an authorized vaccine astatine slightest 8 weeks anterior to enrollment, the institution said.

READ MORE: Safe Streets Group In Belair-Edison Receives $100K Grant From Everytown For Gun Safety

The proceedings volition beryllium conducted successful Australia astatine up to 12 sites and results are expected during the archetypal fractional of 2022. Visit their announcement for much information.

MORE NEWS: COVID-19 In Maryland: Over 200 In ICU Beds, 21 Deaths In Last 24 Hours